Health technology assessment in the United States.
OBJECTIVE
To describe and explore the reasons for the current health technology assessment (HTA) landscape in the United States.


METHODS
Relying on multiple historical literature and other documents as well as drawing on personal experiences and observations, we describe, evaluate, and explain the evolving and dynamic HTA-related evidence landscape.


RESULTS
The present HTA-related landscape is a product of a dynamic, somewhat turbulent path in the United States. Many early aggressive federal efforts beginning in the 1970s were rejected in the 1980s only to be revived by the mid-1990s and continue to strengthen today, likely due to diffusing private sector political opposition from de-linking HTA from policy decisions (e.g., coverage, clinical guidelines) and omitting economic evaluation. Meanwhile, private sector HTA efforts have remained active during the entire period.


CONCLUSIONS
The current HTA-related landscape is at least as dynamic as it has been at any point in its turbulent 30-year history and is likely to continue as health reform in the US is debated once again.
Luce
Bryan
B
United BioSource Corporation, Bethesda, Maryland 20814, USA. bryan.luce@unitedbiosource.com
Cohen
Rebecca Singer
RS
D006291:Health Policy; D049673:History, 20th Century; D049674:History, 21st Century; D013673:Technology Assessment, Biomedical / Q000266:history*; D014481:United States